Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin QD vs BID as add-on to metformin in T2DM
NCT01649297Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Oct 2012; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01649297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649297.